Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRNNASDAQ:BTMDNASDAQ:CURRNASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$10.58+0.6%$9.51$7.08▼$18.25$219.10M0.6675,916 shs60,102 shsBTMDbiote$4.10+2.0%$3.59$3.04▼$8.44$224.31M1.17195,023 shs250,603 shsCURRCURRENC Group$0.86-2.4%$1.56$0.83▼$7.08$39.98M-0.172.07 million shs588,138 shsPHATPhathom Pharmaceuticals$4.09+17.5%$4.48$2.21▼$19.71$285.54M0.151.16 million shs1.92 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+3.65%-1.91%+7.24%-14.11%-43.80%BTMDbiote+2.03%+7.49%+16.52%-12.23%-31.05%CURRCURRENC Group-12.00%-29.32%-41.33%-40.94%+87,999,900.00%PHATPhathom Pharmaceuticals+7.08%+51.97%-27.04%-39.69%-66.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.4154 of 5 stars1.04.00.00.02.20.00.0BTMDbiote3.0757 of 5 stars3.52.00.00.02.43.31.3CURRCURRENC GroupN/AN/AN/AN/AN/AN/AN/AN/APHATPhathom Pharmaceuticals3.8276 of 5 stars4.52.00.00.02.15.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 2.00Hold$7.00-33.84% DownsideBTMDbiote 3.00Buy$8.0095.12% UpsideCURRCURRENC Group 3.50Strong Buy$3.50307.31% UpsidePHATPhathom Pharmaceuticals 3.00Buy$17.60330.32% UpsideCurrent Analyst Ratings BreakdownLatest CURR, PHAT, BTMD, and AMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025PHATPhathom PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $5.005/2/2025PHATPhathom PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $12.005/2/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $20.004/21/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.004/17/2025PHATPhathom PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $10.004/9/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/2/2025PHATPhathom PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/2/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/13/2025BTMDbioteCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.003/10/2025PHATPhathom PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $12.00(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$214.11M1.02N/AN/A$1.35 per share7.84BTMDbiote$199.38M1.13$0.43 per share9.60($0.58) per share-7.07CURRCURRENC Group$46.44M0.86N/AN/AN/A∞PHATPhathom Pharmaceuticals$81.86M3.49N/AN/A($1.27) per share-3.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$59.11M-$3.64N/AN/AN/A-16.33%-7.22%-4.96%7/30/2025 (Estimated)BTMDbiote$3.32M$0.6115.777.59N/A5.20%-32.41%22.26%N/ACURRCURRENC GroupN/AN/A0.00∞N/AN/AN/AN/A7/14/2025 (Estimated)PHATPhathom Pharmaceuticals-$201.59M-$5.24N/AN/AN/A-1,292.14%N/A-79.57%N/ALatest CURR, PHAT, BTMD, and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025AMRNAmarin-$0.06-$0.04+$0.02-$0.04$50.75 millionN/A5/7/2025Q1 2025BTMDbiote$0.06$0.08+$0.02$0.37$47.25 million$48.99 million4/14/2025Q4 2024CURRCURRENC Group-$0.04-$0.70-$0.66-$0.70$10.50 million$11.07 million3/12/2025Q4 2024AMRNAmarin-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/ACURRCURRENC GroupN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.232.11BTMDbioteN/A1.501.16CURRCURRENC GroupN/AN/AN/APHATPhathom PharmaceuticalsN/A5.735.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%BTMDbiote21.68%CURRCURRENC Group56.01%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipAMRNAmarin3.30%BTMDbiote24.00%CURRCURRENC Group17.80%PHATPhathom Pharmaceuticals24.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.71 million402.62 millionOptionableBTMDbiote19454.71 million46.78 millionNot OptionableCURRCURRENC Group246.53 million38.25 millionN/APHATPhathom Pharmaceuticals11069.81 million51.90 millionOptionableCURR, PHAT, BTMD, and AMRN HeadlinesRecent News About These CompaniesPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 15 at 7:59 AM | globenewswire.comCubist Systematic Strategies LLC Makes New Investment in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 14 at 4:40 AM | marketbeat.comPhathom Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:PHAT)May 11, 2025 | americanbankingnews.comPhathom Pharmaceuticals surges 50% following large insider purchaseMay 9, 2025 | msn.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director Acquires $13,000.00 in StockMay 9, 2025 | insidertrades.comAfter Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)May 8, 2025 | zacks.comAvidity Partners Management LP Lowers Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 6, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported, And Analysts Assigned A US$18.63 Price TargetMay 4, 2025 | finance.yahoo.comPhathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $20.00 at HC WainwrightMay 4, 2025 | marketbeat.comMarshall Wace LLP Takes $796,000 Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 4, 2025 | marketbeat.comOracle Investment Management Inc. Reduces Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)May 3, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call TranscriptMay 3, 2025 | seekingalpha.comWhy Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 17.86%May 2, 2025 | aaii.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call TranscriptMay 2, 2025 | msn.comWhy Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 19.35%May 2, 2025 | aaii.comPhathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...May 2, 2025 | finance.yahoo.comRetail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 MissMay 2, 2025 | msn.comPhathom Pharmaceuticals Reports Q1 2025 Financial ResultsMay 2, 2025 | tipranks.comPhathom pharmaceuticals outlines VOQUEZNA expansion targets and cost-saving measures for profitability by 2026May 2, 2025 | msn.comPhathom cuts commercial chief, pares down DTC promotion in cost-saving driveMay 2, 2025 | fiercepharma.comPhathom Pharmaceuticals Eyes Profitability Amid GrowthMay 1, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesCould Palantir’s Latest Partnership Set a Base for a Move Higher?By Chris Markoch | April 23, 2025View Could Palantir’s Latest Partnership Set a Base for a Move Higher?3 Stocks to Buy Now for Tariff ImmunityBy Gabriel Osorio-Mazilli | April 23, 2025View 3 Stocks to Buy Now for Tariff ImmunityAmazon: Why The Great Comeback Rally Could Be About to BeginBy Sam Quirke | May 5, 2025View Amazon: Why The Great Comeback Rally Could Be About to BeginGlobalFoundries Stock Hits Bottom: Is a Rebound Coming?By Thomas Hughes | May 10, 2025View GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?By Nathan Reiff | May 10, 2025View Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?CURR, PHAT, BTMD, and AMRN Company DescriptionsAmarin NASDAQ:AMRN$10.58 +0.06 (+0.57%) Closing price 04:00 PM EasternExtended Trading$10.56 -0.02 (-0.20%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.biote NASDAQ:BTMD$4.10 +0.08 (+1.99%) Closing price 04:00 PM EasternExtended Trading$4.43 +0.33 (+8.05%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.CURRENC Group NASDAQ:CURR$0.86 -0.02 (-2.35%) Closing price 04:00 PM EasternExtended Trading$0.88 +0.02 (+2.41%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.Phathom Pharmaceuticals NASDAQ:PHAT$4.09 +0.61 (+17.53%) Closing price 04:00 PM EasternExtended Trading$4.04 -0.05 (-1.34%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
